Treatment with rituximab plus epcoritamab has achieved rapid and deep responses in follicular lymphoma patients with a high tumor burden.

We’re back with our roundup of the most insightful studies of the year, from the power of brain breaks to groundbreaking ...

Get timely market insights with weekly economic indicators. Click for trends in mortgage apps, labor market signals, and what ...

ORLANDO — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy ...

Congress 2025 took place in Berlin, Germany, a dynamic epicentre known for its blend of innovation, culture, and historical ...

Many people view aging as an inevitable breakdown. Muscle loss, in particular, can carry a sense of dread: the fear that our ...

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

Free clothing, food offered The Geeseytown Lutheran Church, 462 Route 22, Hollidaysburg, will hold a free clothing and ...

JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.

"As a brand, Marshall Cavendish Education has seen Singapore students use our titles for over 57 years. With the expansion of ...

The following highlights showcase key research presented at the European Society for Medical Oncology (ESMO) 2025 Congress.